Mantle Cell Lymphoma (MCL), characterized by its heterogeneity and challenging prognosis, has seen significant therapeutic advances over the past decade. This summary aims to encapsulate the pivotal discussions from the EHA Congress, providing a comprehensive overview of the current state and future directions in MCL management. From the front lines of first-line treatment to the complexities of Relapsed Refractory MCL, our Faculty explore how emerging therapies are reshaping the standard of care and offering new hope to patients worldwide.